China Universal Asset Management Company’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$279K Sell
18,433
-1,761
-9% -$26.6K 0.02% 327
2026
Q1
$220K Buy
20,194
+1,947
+11% +$24.3K 0.02% 345
2025
Q4
$236K Sell
18,247
-1,350
-7% -$17.3K 0.02% 335
2025
Q3
$253K Sell
19,597
-2,794
-12% -$37.3K 0.02% 315
2025
Q2
$399K Buy
22,391
+344
+2% +$5.99K 0.04% 259
2025
Q1
$393K Sell
22,047
-896
-4% -$20.4K 0.04% 265
2024
Q4
$684K Buy
22,943
+2,129
+10% +$45.1K 0.06% 211
2024
Q3
$325K Buy
20,814
+8,172
+65% +$148K 0.04% 261
2024
Q2
$217K Sell
12,642
-7,938
-39% -$140K 0.03% 228
2024
Q1
$322K Buy
20,580
+8,217
+66% +$121K 0.04% 233
2023
Q4
$185K Buy
12,363
+9,624
+351% +$129K 0.04% 211
2023
Q3
$44.2K Buy
2,739
+1,347
+97% +$38.8K 0.01% 235
2023
Q2
$57.8K Sell
1,392
-37
-3% -$2.3K 0.02% 182
2023
Q1
$85.9K Buy
1,429
+363
+34% +$29K 0.03% 130
2022
Q4
$78.2K Buy
1,066
+85
+9% +$6.4K 0.03% 126
2022
Q3
$75K Buy
+981
New +$76.5K 0.03% 116

Other funds holding NVCR

China Universal Asset Management Company's NVCR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its NovoCure (NVCR) stake by 8.7% in Q2 2026, selling an estimated $26.6K and leaving 18,433 shares worth $279K. The position accounts for 0.02% of the portfolio, ranked #327.

China Universal Asset Management Company first reported a position in NVCR in Q3 2022 and has held it in 16 quarters since. The position peaked at $684K in Q4 2024. 34 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • China Universal Asset Management Company held 18,433 shares of NovoCure worth $279K as of Q2 2026.
  • China Universal Asset Management Company sold 1,761 NovoCure shares in Q2 2026, an estimated $26.6K.
  • NovoCure made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #327 holding.
  • China Universal Asset Management Company first reported a position in NovoCure in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's NovoCure position peaked at $684K in Q4 2024.
  • 34 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.